Tags

Type your tag names separated by a space and hit enter

A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders.
J Clin Psychiatry. 2004 Nov; 65(11):1531-6.JC

Abstract

BACKGROUND

The purpose of this study was to examine the effectiveness and tolerability of quetiapine for aggression, hyperactivity, and self-injury in pervasive developmental disorders (PDDs).

METHOD

The medical records of all patients with PDDs diagnosed according to DSM-IV criteria and treated with quetiapine were retrospectively reviewed. Patients who received quetiapine for at least 4 weeks and who were not concurrently treated with another antipsychotic or mood stabilizer were included. Improvement was measured with the Clinical Global Impressions-Improvement scale (CGI-I), with response determined by ratings of "much improved" or "very much improved." Data were collected from May 15, 2003 through November 30, 2003.

RESULTS

Of 857 records reviewed, 20 patients (16 male, 4 female) (mean +/- SD age = 12.1 +/- 6.7 years; range, 5-28 years) received a quetiapine trial (mean +/- SD dosage = 248.7 +/- 198.4 mg/day; range, 25-600 mg/day) over a mean duration of 59.8 +/- 55.1 weeks (range, 4-180 weeks). Eight (40%) of 20 patients were judged "responders" to quetiapine; the mean CGI-I score for the entire group was 3.0 +/- 1.1 (minimally improved). A statistically significant improvement (p = .002) was found between a mean pretrial CGI-Severity of Illness scale (CGI-S) score of 5.1 +/- 0.6 (markedly ill) and a posttrial CGI-S score of 4.2 +/- 1.1 (moderately ill). Adverse effects occurred in 50% (N = 10) of patients and led to drug discontinuation in 15% (N = 3) of patients.

CONCLUSION

Quetiapine was modestly effective for maladaptive behavior in patients with a PDD. Controlled studies are needed to further assess these preliminary findings.

Authors+Show Affiliations

Department of Psychiatry, Indiana University School of Medicine and Christian Sarkine Autism Treatment Center, James Whitcomb Riley Hospital for Children, Indianapolis, Ind. 46202-4800, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

15554768

Citation

Corson, Adam H., et al. "A Retrospective Analysis of Quetiapine in the Treatment of Pervasive Developmental Disorders." The Journal of Clinical Psychiatry, vol. 65, no. 11, 2004, pp. 1531-6.
Corson AH, Barkenbus JE, Posey DJ, et al. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry. 2004;65(11):1531-6.
Corson, A. H., Barkenbus, J. E., Posey, D. J., Stigler, K. A., & McDougle, C. J. (2004). A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. The Journal of Clinical Psychiatry, 65(11), 1531-6.
Corson AH, et al. A Retrospective Analysis of Quetiapine in the Treatment of Pervasive Developmental Disorders. J Clin Psychiatry. 2004;65(11):1531-6. PubMed PMID: 15554768.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. AU - Corson,Adam H, AU - Barkenbus,John E, AU - Posey,David J, AU - Stigler,Kimberly A, AU - McDougle,Christopher J, PY - 2004/11/24/pubmed PY - 2004/12/22/medline PY - 2004/11/24/entrez SP - 1531 EP - 6 JF - The Journal of clinical psychiatry JO - J Clin Psychiatry VL - 65 IS - 11 N2 - BACKGROUND: The purpose of this study was to examine the effectiveness and tolerability of quetiapine for aggression, hyperactivity, and self-injury in pervasive developmental disorders (PDDs). METHOD: The medical records of all patients with PDDs diagnosed according to DSM-IV criteria and treated with quetiapine were retrospectively reviewed. Patients who received quetiapine for at least 4 weeks and who were not concurrently treated with another antipsychotic or mood stabilizer were included. Improvement was measured with the Clinical Global Impressions-Improvement scale (CGI-I), with response determined by ratings of "much improved" or "very much improved." Data were collected from May 15, 2003 through November 30, 2003. RESULTS: Of 857 records reviewed, 20 patients (16 male, 4 female) (mean +/- SD age = 12.1 +/- 6.7 years; range, 5-28 years) received a quetiapine trial (mean +/- SD dosage = 248.7 +/- 198.4 mg/day; range, 25-600 mg/day) over a mean duration of 59.8 +/- 55.1 weeks (range, 4-180 weeks). Eight (40%) of 20 patients were judged "responders" to quetiapine; the mean CGI-I score for the entire group was 3.0 +/- 1.1 (minimally improved). A statistically significant improvement (p = .002) was found between a mean pretrial CGI-Severity of Illness scale (CGI-S) score of 5.1 +/- 0.6 (markedly ill) and a posttrial CGI-S score of 4.2 +/- 1.1 (moderately ill). Adverse effects occurred in 50% (N = 10) of patients and led to drug discontinuation in 15% (N = 3) of patients. CONCLUSION: Quetiapine was modestly effective for maladaptive behavior in patients with a PDD. Controlled studies are needed to further assess these preliminary findings. SN - 0160-6689 UR - https://www.unboundmedicine.com/medline/citation/15554768/A_retrospective_analysis_of_quetiapine_in_the_treatment_of_pervasive_developmental_disorders_ L2 - http://www.psychiatrist.com/jcp/article/pages/2004/v65n11/v65n1115.aspx DB - PRIME DP - Unbound Medicine ER -